CRSP · CRISPR Therapeutics reported Q3 2026 CASGEVY revenue of $99 million, up…

CRISPR Therapeutics reported Q3 2026 CASGEVY revenue of $99 million, up 30% quarter-over-quarter and nearly 6x year-over-year, but total revenue of $12.7 million (collaboration + grant) missed the $16.6 million consensus. Net loss per share was -$1.15, wider than the consensus estimate of -$1.06, driven by higher R&D and acquired IPR&D expenses. The CASGEVY growth and pipeline progress are offset by the EPS miss and revenue shortfall.

• CASGEVY revenue of $99 million in Q3 2026, up 30% QoQ and nearly 6x vs Q3 2025
• Total revenue $12.7 million (collaboration $12.3M + grant $0.3M) vs consensus $16.6M
• Net loss per share -$1.15 (GAAP diluted) vs consensus -$1.06
• Net loss $111.4 million vs $106.4 million in Q3 2025